NHI to reimburse Reminyl for additional indications from Feb.

The NHI reimbursement for the additional indications of Reminyl, an anti-schizophrenia drug, will be effected from Feb. 1 covering the Alzheimer disease patients with cerebral vascular conditions according to the revised ordinance of "Standards for NHI payment application and its detailed particulars".

The new ordinance described that the NHI reimbursement for Reminyl be approved from Feb. f...